The UK Biobank Pharma Proteomics Project (UKB-PPP) has recently announced its intention to use Olink® Explore HT to measure more than 5400 proteins in 600,000 samples from UKB participants.
This collaboration between 14 leading biopharmaceutical companies and UKB represents the most significant study of its kind. This project will generate a comprehensive map of protein levels throughout the human body, advancing understanding of disease.
UKB-PPP plans to analyze 300,000 samples initially, then seek supplemental funding to analyze an additional 300,000 samples.
This work represents a defining moment for biomedical science, fully establishing true population-scale proteomics and facilitating breakthrough discoveries able to shape human health.
The project will offer the scientific community an unrivaled data resource that is expected to underpin pioneering discoveries across the entire field of human biology.
Building on a legacy of success
The UKB-PPP pilot phase employed the Olink Explore 3072 to measure approximately 3000 proteins in over 54,000 UKB participants.
Three landmark publications from consortium members appeared in Nature in late 2023, and this unique dataset is now available to the wider scientific community. Access to this data offered the community a ‘measure once, query often’ opportunity to generate a wide range of impactful publications across a diverse range of biological questions.
In 2024 alone, more than 100 peer-reviewed articles citing the use of Olink data and using the UKB-PPP dataset were published, encompassing all major disease areas represented in the UK Biobank.
These studies showcase the project’s capacity to deliver meaningful new discoveries relevant to future human healthcare and drug development.
Transformative insights into human biology
The current UKB-PPP project has seen an order-of-magnitude increase in size since its pilot phase, offering the potential to advance the field’s understanding of the biological mechanisms underlying human health. Such significant advances have not been seen since the completion of the Human Genome Project.
Scientists will now be able to understand the impact of genetic differences as well as lifestyle and environmental factors on human health, thanks to this combination of Olink technology and the capacity to measure thousands of proteins at population scale using data from the world’s most well-characterized biobank.
The project will also ensure the broader applicability of the generated data by leveraging the rich ethnic diversity among the UKB participants. Increasing the genetic diversity of population-scale multiomic studies will be a key factor in implementing precision medicine in global healthcare.
Though the release of this new proteomic dataset will inevitably lead to innovative approaches and unexpected findings, some key focus areas are expected.
- Many new associations are being discovered between genetic variants and protein levels (pQTLs). These discoveries are key to the identification of proteins with causal roles in disease, potentially guiding drug repurposing or leading to the development of new, robust drug targets.
- The identification of novel pathway associations with disease improves understanding of pathophysiology and helps highlight commonalities between diverse disease types.
- Identifying new protein biomarkers will be key to predicting, diagnosing, and prognosticating a diverse range of diseases. This work will expedite the adoption of protein-based risk scores that complement and enhance current genetic and clinical risk scores, positively impacting preventive medicine.
A resource to accelerate the next generation of healthcare
The new UKB-PPP resource was released to the scientific community at the start of 2026. This new resource offers a plethora of information with enormous significance to the field’s understanding of human health.
For the past 20 years, genetic data has played a major role in drug development, but these developments mark the dawn of a new era.
The participation of 14 leading biopharmaceutical companies in the UKB-PPP initiative highlights proteomics’ central role in next-generation healthcare. Proteomics has enormous potential to drive improvements in future healthcare, offering vital real-time insights into dynamic biological changes while leveraging minimally invasive samples.
This approach will benefit early diagnosis, the selection of more effective and tailored therapies, disease progression monitoring, and therapeutic response and outcome evaluation.
Population-scale proteomics has led to remarkable discoveries in the last few years, and these discoveries have only scratched the surface of what is possible.
About Olink®- Part of Thermo Fisher Scientific
Olink’s mission is to accelerate proteomics together with the scientific community, to understand real-time biology and gain actionable insights into human health and disease. Our innovative solutions deliver highly sensitive and accurate protein quantification, giving scientists the power to investigate complex biological processes with precision.
One platform. Endless possibilities.
Explore up to 5,400 proteins with high specificity, transparent data, and the flexibility to answer any research question. Meet the next-generation proteomics platform trusted by the scientific community, from small academic research teams through to leading pharma companies.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.